Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 : Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R.The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Dexamethasone alone or Dexamethasone +Tocilizumab administration to patients enrolled in the CORIMUNO-19 cohort.Tocilizumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation.Patients who will chose not to receive Tocilizumab will receive standard of cares.Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care (including Dexamethasone) treated patients.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 08. Juni Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: July 20, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2022, Last updated: June 15, 2022 |
|---|
| Study ID: |
NCT04476979 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG00345987X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG00345987X | ||
| 003 | DE-627 | ||
| 005 | 20230425194427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG00345987X | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04476979 | ||
| 035 | |a (UBBS_Klinische_Studien)APHP200375-TOCIDEX | ||
| 035 | |a (UBBS_Klinische_Studien)2020-001246-18 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 |b Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: July 20, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2022, Last updated: June 15, 2022 | ||
| 520 | |a The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R.The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Dexamethasone alone or Dexamethasone +Tocilizumab administration to patients enrolled in the CORIMUNO-19 cohort.Tocilizumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation.Patients who will chose not to receive Tocilizumab will receive standard of cares.Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care (including Dexamethasone) treated patients | ||
| 650 | 2 | |a Infections | |
| 650 | 2 | |a Communicable Diseases | |
| 650 | 2 | |a Virus Diseases | |
| 650 | 2 | |a Coronavirus Infections | |
| 650 | 2 | |a Respiratory Tract Infections | |
| 650 | 2 | |a Severe Acute Respiratory Syndrome | |
| 650 | 2 | |a RNA Virus Infections | |
| 650 | 2 | |a Coronaviridae Infections | |
| 650 | 2 | |a Nidovirales Infections | |
| 650 | 2 | |a Respiratory Tract Diseases | |
| 650 | 4 | |a Medical Condition: Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Respiratory Tract Infections, Respiratory Tract Disease | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 08. Juni |
| 773 | 1 | 8 | |g year:2022 |g day:08 |g month:06 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04476979 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 08 |c 06 | ||